Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases
Matthias Bartneck(DWI – Leibniz Institute for Interactive Materials), Frank Tacke(Charité - Universitätsmedizin Berlin), Larissa Yokota Rizzo(RWTH Aachen University), Klaudia Theresa Warzecha(Universitätsklinikum Aachen), Katharina M. Scheyda(RWTH Aachen University), Twan Lammers(RWTH Aachen University), Kanishka Hittatiya(University of Bonn), Tom Luedde(Düsseldorf University Hospital), Gert Storm(Yong In University), Christian Trautwein(TUM Klinikum)
Cited by 141
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
|Nature Reviews Gastroenterology & Hepatology|2011|1.4k
Tumor targeting via EPR: Strategies to enhance patient responses
|Advanced Drug Delivery Reviews|2018|1.2k